Alchem International Guarantees Continued Production of APIs

Global provider of phytochemicals to the pharmaceutical industry Alchem International has confirmed its commitment to ongoing production of hyoscine hydrobromide, hyoscyamine and digoxin, three APIs commonly used in travel sickness, irritable bowel syndrome and heart condition therapies respectively. Alchem’s commitment to continue manufacturing these ingredients means the end of recent market uncertainty and ensures pharmaceutical manufacturers all over the world will have a secure supply of them in the future.

As part of its regulatory support service, Alchem International is supporting hyoscine hydrobromide and hyoscyamine registrations through CTD DMF and digoxin registration through CTD DMF and EU CEP.  All three products are manufactured at Alchem’s WHO and FDA GMP audited facility in Ballabhgargh and written confirmation is available per new European Union law for EU import. Additionally, the company has recently invested in dedicated production and packaging facilities for other small-scale APIs. These include tropane alkaloids such as methscopolamine bromide (CTD DMF), scopolamine base (CTD DMF), cimetropium bromide (CTD DMF) and scopine HCL.

Robin Ward, Business Development Director at Alchem International, commented: “Offering consistent supply and best-in-class regulatory support is central to Alchem International’s promise to customers, and this is what prompted our investment and our commitment to the ongoing production of these three APIs. Decisions by other API suppliers to cease hyoscine hydrobromide, hyoscyamine and digoxin production and regulatory support have caused some uneasiness among pharmaceutical manufacturers, which we can help resolve. This is a significant undertaking and one we are proud to make, because we understand that consistent supply of all APIs is vital, not only the mainstream ones.”

Alchem International Ltd, +41 91 604 6921, rward@alcheminternational.com, www.alcheminternational.com.